CAR-T Cell Therapies Market with a Target Valuation of USD 7.9 billion by 2032 | Dynamic CAGR of 13.8%

The rising incidence of cancer, especially hematological malignancies like leukemia and lymphoma, has been a driving force behind the growth of the CAR-T cell therapies market. These therapies show promise in treating patients who have not responded to traditional treatments.

New York, Jan. 17, 2024 (GLOBE NEWSWIRE) -- According to, the CAR-T cell Therapies market size is projected to surpass around USD 7.9 billion by 2032, from USD 2.5 Billion, and is poised to reach a CAGR of 13.8% from 2024 to 2033.

A type of cancer immunotherapy treatment that makes use of T-cells, which are genetically modified in a lab, allowing the T-cell to target and kill the cancer cells completely, is known as CAR-T cell therapy. The three main steps included in this therapy is engineering of T-cells, connecting T-cells and insertion of the CAR T-cells into the body. Being approved by FDA, the therapy treats some type of lymphomas, leukemia’s along with several myeloma.

Get a Complete and Professional sample PDF @

CAR-T Cell Therapies Market

Key Takeaway

  • The rise in number of children and adults developing cancer, demands the effective therapeutic treatment.
  • The impeding factor for the expansion of CAR-Tcell therapies market is the high cost of treatment.
  • According to drug type analysis, axicabtagene ciloleucel is accounted for highest revenue generation in 2023.
  • The incorporation of CAR-T cell therapies program in various research institute, leads the research segment at the forefront.
  • The lymphoma segment is accounted to hold 56.9% of the CAR-T cell therapies market in 2023.
  • The investment of market key players in R&D activities, offers more opportunities for the growth of the market.

Factors affecting the growth of the CAR-T cell theparies Market

  • Increase in the geriatric population: Due to rise in the population of aged people, there is rise in demand for CAR-T cell therapies.
  • Rising awareness: The CAR-Tcell program conduction in various research institues, provides satisfactory knowledge and rises the awareness of the treatment among the people.
  • Technological Advances: The new and innovative technologies in cancer treating therapies and medical treatments are helping to increase this market by offering greater convenience and increase the market growth.
  • Funding policies in developed countries: The government focuses on increasing awareness about drugs and treatment and provides different funding policies for advanced technologies as well as improving healthcare facilities in developed countries.

Top Trends in Global CAR-T cell therapies Market

The introduction of KYMRIAH(tisagenlecleucel), which is a CD19-directed genetically altered related T cell immunotherapy by Novartis AG, helps in the treatment of B-cell precursor acute lymphoblastic leukemia. This modification has revolutionised the CAR-T cell therapy for effective treamtment of cancer. Researchers are still focusing to upscale the efficacy and safety of the CAR-T cell therapies, and lower its side effects.

Market Growth

The rise in prevalence of cancer worldwide is anticipated to excel the development of CAR-T cells for therapeutic applications. The involvement of chimeric immunoreceptors for finding the T-cells and helping them to kill the cancerous cells played a vital role in CAR-T cell therapy. The research and development activities for cancer treatment which makes use of chimeric antigen receptor continues to grow. Many countries are involved to validate the efficacy of car-T cell therapies, which will help to effectively eradicate the cancer related problems.

Regional Analysis

North America is accounted to hold the largest market share of 61.49%, dominating the Car-T cell therapies market in 2023. The region being dominant is by virtue of rise in chronic diseases such as autoimmune disorders and cancer. For example, the number of novel cancer cases and deaths are 1,958,310 and 6,09,820 in North American region, according to America Cancer Society. In addition to this, investments for research & development activities by major key players played a vital role to excel the market.

Owing to the rise in consciousness of Car-Tcell therapies and increasing number of target population, Asia-Pacific market is expected to hold the maximum revenue share of car-T cell therapies in 2023.

Uncover the actionable insights tailored for your business strategy. Request our brochure to get more

CAR-T Cell Therapies Market Region

Scope of the Report

Report AttributesDetails
Market Value (2023)USD 2.5 Billion
Forecast Revenue 2032USD 7.9 Billion
CAGR (2023 to 2032)13.8%
North America Revenue Share61.49%
Base Year2023
Historic Period2018 to 2022
Forecast Year2024 to 2033

Market Drivers

The rise in prevalence of cancer in North America is the major driving factor to upsurge the market growth of car-T cell therapies. According to statista 2022, North America had maximum prevalence ratio in 2020, from twelve months. The prevalence rate for each cancer in this region was 588 per 1,00,000 population. In addition to this, the rise in number of adults and children developing cancer demands for more advanced therapeutic treatments, which in turn leads to satisfactory growth of the market.

Market Restraints

One of the major factor hampering the market growth of car-T cell market is the high cost of the treatment. Many factors depends for the rise in the cost of treatment such as manufacturing process, specialized requirements of healthcare and personalized nature of the therapy.


The rise in adoption of novel medicines of car T cell therapies and increasing awareness regarding the same, provides lucrative opportunities for the growth of the car T cell therapies market. There is enhanced clinical trial activities and commercialization of car T cell therapy, helping to offer major opportunities for expanding the market dimensions during the forecast period.

Instant Access Now | Purchase This Exclusive Research Report

Report Segmentation of the car T cell therapies Market

Drug type analysis

Based on drug type analysis, the market is disjointed into axicabtagene ciloleucel, tisagenlecleucel, brexucabtagene autoleucel and lisocabtagene maraleucel segments. Owing to the rise in approval of axicabtagene ciloleucel medicine for the purpose of relapsed refractory large B-cell lymphoma and refractory follicular lymphoma treatment, the axicabtagene ciloleucel segment holds a large market share of 32.4%, dominating the car T cell therapies market in 2023.

On the flip side, brexucabtagene autoleucel segment is anticipated to have the fastest market growth due to adoption of Car T therapies for treating refractory B- cell precursor acute lymphoblastic leukemia.

Modality Analysis

The global CAR T cell therapies market is bifurcated into research and commercialization based on modality analysis. The research segment accounted to hold the largest market share in 2023, this dominance owes to the active participation of various research institutes in operating the CAR T cell therapy programs, promoting the treatment of cancer.

Target antigen analysis

As far as target antigen is considered, the global Car T cell therapies market is segmented into CD19, CD22 and BCMA. The CD19/CD22 target antigen holds the large market revenue share in 2023. The CD19 has effectively treated patients with B-cell malignancies.

Indication Analysis

Based on indication analysis, the market is categorised into lymphoma, acute lymphatic leukemia and autoimmune disorders. For treating different types of lymphomas, a noticeable number of approved CAR T cell therapies are employed. The CAR T cell therapies are approved by Food & Drug Administration (FDA). The treatment of multiply replaced large B cell lymphoma has advanced due to the CAR T cell therapies targeting CD19. Hence the lymphoma segment is accounted to hold a large market share of 57.1% in 2023.

End User Analysis

Based on end user analysis, the global CAR T cell therapies market is segmented into hospitals and cancer research institutes. The well equipped operation theatres, increase in patient admission and advanced buying power, has led the hospital segment to dominated the market by accounting to hold a large market share of 62.8% in 2023. Due to the availability of different types of treatments and rise in number of cancer centres, the cancer research institute segment is expected to grow at the highest CAGR.

CAR-T Cell Therapies Market Size

Gain expert insights and supercharge your growth strategies. Request our market overview sample now:

Market Segmentation

Drug Type Analysis

  • Axicabtagene ciloleucel
  • Tisagenlecleucel
  • Brexucabtagene autoleucel
  • Lisocabtagene maraleucel

Modality analysis

  • Research
  • Commercialization

Target Antigen analysis

  • CD19
  • CD22
  • BCMA

Indication analysis

  • Lymphoma
  • Acute lymphatic leukemia
  • Autoimmune disorders

End User Analysis

  • Hospitals
  • Cancer research institutes

By Geography

  • North America
    • The US
    • Canada
    • Mexico
  • Western Europe
    • Germany
    • France
    • The UK
    • Spain
    • Italy
    • Portugal
    • Ireland
    • Austria
    • Switzerland
    • Benelux
    • Nordic
    • Rest of Western Europe
  • Eastern Europe
    • Russia
    • Poland
    • The Czech Republic
    • Greece
    • Rest of Eastern Europe
  • APAC
    • China
    • Japan
    • South Korea
    • India
    • Australia & New Zealand
    • Indonesia
    • Malaysia
    • Philippines
    • Singapore
    • Thailand
    • Vietnam
    • Rest of APAC
  • Latin America
    • Brazil
    • Colombia
    • Chile
    • Argentina
    • Costa Rica
    • Rest of Latin America
  • Middle East & Africa
    • Algeria
    • Egypt
    • Israel
    • Kuwait
    • Nigeria
    • Saudi Arabia
    • South Africa
    • Turkey
    • United Arab Emirates
    • Rest of MEA

Impact of Macroeconomic factors
While inflationary pressure started to ease in 2023, economies continues to face uncertainty. Regarding healthcare sector, inflation will be continued to elevate in 2024. The rising costs triggers the patients to postpone or stop treatments in H2 2023. In addition to this, the prices of drug continue to grow with the increase in inflation rate.

Recent Development of the CAR-T cell Therapies Market

  • In June 2022: A leader in biopharmaceuticals, Bristol Myers Squibb company, obtained the FDA authorization for Breyanzi CAR T cell therapy for treating refractory large B-cell lymphoma.
  • In September 2020: A partnership between Seattle genetics, Inc and Merck, considered the oncology studies, conducting a vast ranging joint development program in several cancers.

Competitive Landscape

The rise in number of key players in CAR T cell therapies market led to the rise in competitive struggle in the market. The focus on R&D activities by various market key players for the development of CAR T cell therapies products to cure various types cancer led to the growth of the market.
Some of the prominent key players are as follows:

  • Juno Therapeutics, Inc.
  • Bristol-Myers Squibb Company
  • Bluebird Bio, Inc.
  • Gilead Sciences, Inc.
  • Merck & Co., Inc.
  • Pfizer, Inc.
  • Sorrento Therapeutics, Inc.
  • Merck KGaA
  • Amgen Inc.
  • Eureka Therapeutics Inc.
  • Calyxt Inc.
  • Autolus Therapeutics
  • CARsgen Therapeutics Co.Ltd.
  • Poseida Therapeutics, Inc.
  • Fortress Biotech, Inc.
  • Other Key Players

Browse More Related Reports

About Us:

Market.US (Powered by Prudour Pvt Ltd) specializes in in-depth market research and analysis and has been proving its mettle as a consulting and customized market research company, apart from being a much sought-after syndicated market research report-providing firm. Market.US provides customization to suit any specific or unique requirement and tailor-makes reports as per request. We go beyond boundaries to take analytics, analysis, study, and outlook to newer heights and broader horizons.

Follow Us on LinkedIn

Our Blog: 


Contact Data